A research note made public on Tuesday reported that Truist Financial had become a new shareholder in Evolent Health (NYSE: EVH). It was The Fly that provided us with the information. The stock of the information technology company has been given a “hold” rating, and the brokerage firm has established a price objective of $33.00 for the stock. The fact that the target price proposed by Truist Financial is higher than the current price of the stock, which is 3.74%, indicates that there is room for growth in the market for the stock.
In addition, the organization has been the focus of attention for earlier research investigations carried out by various analysts. In a research report published on Wednesday, October 12, Canaccord Genuity Group announced that they would be lowering their price objective for Evolent Health from $55.00 to $48:00. The report was issued on Wednesday. The “buy” rating and target price of $55.00 that BTIG Research had previously assigned to Evolent Health was reduced to $45.00 in a research report published on October 12. In a research report published on August 3, Evolent Health went from an “underweight” rating to a “neutral” rating and raised their target price on the stock from $35.00 to $40.00 in a research report that was published on August 3. Piper Jaffray also increased its target price on the stock. In a study published on July 25, Cowen announced that they would be increasing their target price for Evolent Health to $52.00. In a report published on Wednesday, October 12, Canaccord Genuity Group lowered their recommendation on Evolent Health from a “buy” rating to a “hold” rating in a report that was Despite this change; they did not change their price target from $55.00. Ten analysts have recommended purchasing the stock, while only two have recommended maintaining the current position in the stock. The current average rating for Evolent Health is “Moderate Buy,” and the price target is $46.09 per share, according to information that Bloomberg provided.
As trading got underway on Tuesday, the price of a share of Evolent Health was $31.81 per share. The stock currently trades at a market value of $2.91 billion and carries a price-to-earnings ratio of -99.41. It has a beta value of 1.70. The stock’s price is currently trading at $35.31 according to its fifty-day simple moving average, while its 200-day simple moving average can be found at $32.38. The ratio of total assets to current assets is 1.23, the ratio of current assets to total assets is also 1.23, and the ratio of debt to equity is 0.46. During the previous calendar year, Evolent Health’s price fluctuated between $21.36 and $39.78.
Evolent Health (NYSE: EVH) made the most recent quarterly earnings report available to the public on Tuesday, August 2, 2018, which was also a Tuesday. The information technology company’s earnings per share for the quarter came in at $0.02, which was $0.07 higher than the analysts’ consensus estimate of $0.05, which the company had provided. Even though market watchers anticipated that the company would bring in sales totaling $293.31 million during the quarter, the actual amount it brought in was $319.94 million. Evolent Health had a negative net margin of 2.63%, while the return on equity for the company was positive at 0.41%. Sell-side analysts predict Evolent Health will make $0.056 per share in profits during the current fiscal year.
On Friday, August 12, Jonathan Weinberg, who serves as general counsel for Evolent Health, exercised his option to sell 14,335 shares of the company’s stock. Jonathan Weinberg exercised his option to sell 14,335 shares of the company’s stock. The sale of the stock resulted in a total revenue of 501,151.60 dollars and an average price of $34.96 per share for each purchased share. The general counsel is now the proud owner of 135,103 shares of company stock, which have a combined value of approximately $4,723,200.88 as a direct result of the transaction that took place earlier. If you follow this link, you will be taken to a document submitted to the Securities and Exchange Commission (SEC). The document contains an in-depth explanation of the reported transaction to the SEC. On Friday, August 12, Jonathan Weinberg, who serves as general counsel for Evolent Health, exercised his option to sell 14,335 shares of the company’s stock. Jonathan Weinberg exercised his option to sell 14,335 shares of the company’s stock.
A total of shares sold were worth $501,151.60 dollars, and the average price that each share was sold for was $34.96. The general counsel now has ownership of 135,103 business shares that have a combined value of $4,723,200.88 as a result of the successful completion of the sale. If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed. You can simply ignore this link if you do not want to follow it. In addition, Mary Bridget Duffy, a company director, sold 7,500 shares of the company’s stock on Tuesday, August 16. The total amount received for the sale of the shares was $248,475.00, and the price paid on average for each share was $33.13. When the transaction is finalized, the director will have obtained 50,450 shares. Based on the current market price, this amount of stock is estimated to be worth $1,671,408.50. Disclosures that are related to the sale might be found in this section of the website. During the most recent quarter of the company’s fiscal year, company insiders sold 90,269 shares of company stock for a total price of $3,238,910. At present, company insiders collectively own 4.20% of the total number of shares outstanding.
Recently, several hedge funds and institutional investors have adjusted the total amount of stock held in their portfolios by either increasing or decreasing the amount of stock they hold. The amount of Evolent Health stock owned by Captrust Financial Advisors increased by 254.4% during the second quarter of the current fiscal year. In the most recent fiscal quarter, Captrust Financial Advisors increased their holdings in the technology company’s stock by purchasing an additional 1,262 shares. This brings their total holdings to 1,758 shares of the company’s stock, which has a value of $54,000. In the first three months of 2018, Nisa Investment Advisors LLC made a 67.9% purchase of additional Evolent Health stock, increasing the percentage of the company’s stock it owned. Nisa Investment Advisors LLC now holds a total of 2,250 shares of the technology company’s stock, which has a value of $73,000. This is a result of the purchase of an additional 910 shares during the most recent fiscal quarter. During the first three months of the year, AdvisorShares Investments LLC acquired a new position in shares of Evolent Health at a value of approximately $192,000. Oppenheimer & Co., Inc. increased its overall holdings in Evolent Health during the first quarter by investing approximately 206,000 additional dollars in the company through new investments. This is the final and most important point that needs to be made, as it relates to the fact that Convergence Investment Partners LLC increased its holdings in Evolent Health by approximately $228,000 during the first quarter. The stock is held by hedge funds and other institutional investors for 96.81% of its total value, making these investors the most valuable shareholders.
Evolent Health LLC, a wholly owned subsidiary of Evolent Health, is a company that delivers clinical and administrative solutions to payers and providers in the United States. Evolent Health, Inc. is a company that operates in the healthcare industry. The business is organized into two distinct branches: the Evolent Health Services Division and the Clinical Solutions Branch. Evolent Health Services offers a complete administrative and clinical platform that can be used to run health plans and manage the overall health of a population.